Publications 2011

1. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PloS one, 2011. 6(6): e20740.

2. Broen K, Levenga H, Vos J, van Bergen K, Fredrix H, Greupink-Draaisma A, Kester M, Falkenburg JH, de Mulder P, de Witte T, Griffioen M, Dolstra H. A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR. PloS one, 2011. 6(6): e21699.

3. de Keijzer S, Meddens MB, Kilic D, Joosten B, Reinieren-Beeren I, Lidke DS, Cambi A. Interleukin-4 Alters Early Phagosome Phenotype by Modulating Class I PI3K Dependent Lipid Remodeling and Protein Recruitment. PloS one, 2011. 6(7): e22328.

4. Oosting M, Ter Hofstede H, Sturm P, Adema GJ, Kullberg BJ, van der Meer JW, Netea MG, Joosten LA. TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of Borrelia Spirochetes. PloS one, 2011. 6(10): e25998.

5. Tel J, Torensma R, Figdor CG, de Vries IJ. IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1. J Invest Dermatol, 2011. 131(4): 900-6.

6. Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG, Tacken PJ, de Vries IJ. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol, 2011. 41(4): 1014-23.

7. Plantinga TS, van Maren WW, van Bergenhenegouwen J, Hameetman M, Nierkens S, Jacobs C, de Jong DJ, Joosten LA, van't Land B, Garssen J, Adema GJ, Netea MG. Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics. Clinical and vaccine immunology : CVI, 2011. 18(4): 621-8.

8. van Spriel AB. Tetraspanins in the humoral immune response. Biochemical Society transactions, 2011. 39(2): 512-7.

9. Cruz LJ, Tacken PJ, Bonetto F, Buschow SI, Croes HJ, Wijers M, de Vries IJ, Figdor CG. Multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Molecular pharmaceutics, 2011. 8(2): 520-31.

10. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. European journal of cancer, 2011. 47(12): 1883-9.

11. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. 29(22): 3016-22.

12. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, van Krieken JH, Adema GJ, Figdor CG, de Vries IJ. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. The Journal of clinical investigation, 2011. 121(8): 3100-8.

13. Zeelenberg IS, van Maren WW, Boissonnas A, Van Hout-Kuijer MA, Den Brok MH, Wagenaars JA, van der Schaaf A, Jansen EJ, Amigorena S, Thery C, Figdor CG, Adema GJ. Antigen localization controls T cell-mediated tumor immunity. Journal of immunology, 2011. 187(3): 1281-8.

14. Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, Falkenburg JH, Schaap N, de Witte TM, van der Voort R, Dolstra H. PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation. Cancer research, 2011. 71(15): 5111-22.

15. Veenbergen S, van Spriel AB. Tetraspanins in the immune response against cancer. Immunology letters, 2011. 138(2): 129-36.

16. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood, 2011. 118(26): 6836-44.

17. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother, 2011. 60(2): 249-60.

18. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Seminars in immunology, 2011. 23(1): 12-20.

19. Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica, 2011. 96(2): 291-7.

20. van den Berk LCJ, Jansen BJH, Siebers-Vermeulen KGC, Huijsi T, Roelofs H, Kogler G, Figdor CG, Torensma R. The Tissue Origin and Culture History of Mesenchymal Stem Cells Affect their Performance in Osteoblastic Differentiation. Tissue Engineering and Regenerative Medicine, 2011. 8(1): 96-105.

21. Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood, 2011. 117(5): 1516-21.

22. de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, Adema GJ, Punt CJ, Rivoltini L, Schuler G, Coulie PG, Lucas S. Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. Clin Cancer Res, 2011. 17(4): 841-8.

23. Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Bene MC, Berger U, Buchner T, Burnett A, Cross NC, de Witte TJ, Dohner H, Dombret H, Einsele H, Engelich G, Foa R, Fonatsch C, Gokbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S. The European LeukemiaNet: achievements and perspectives. Haematologica, 2011. 96(1): 156-62.

24. Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kroger N, Rocha V. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 2011. 25(1): 75-81.

25. Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Eradicating cancer cells: struggle with a chameleon. Oncotarget, 2011. 2(1-2): 99-101.

26. van Bijnen ST, Withaar M, Preijers F, van der Meer A, de Witte T, Muus P, Dolstra H. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. Experimental hematology, 2011. 39(7): 751-62 e3.

27. Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM, Torensma R, Teerenstra S, Mulders PF, Vissers KC, Punt CJ, de Vries IJ, van Herpen CM. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res, 2011. 17(13): 4541-9.

28. Theodoridis AA, Eich C, Figdor CG, Steinkasserer A. Infection of dendritic cells with herpes simplex virus type 1 induces rapid degradation of CYTIP, thereby modulating adhesion and migration. Blood, 2011. 118(1): 107-15.

29. de Witte T. Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?. Clinical lymphoma, myeloma & leukemia, 2011. 11 Suppl 1: S46-8.

30. Jansen BJ, Sama IE, Eleveld-Trancikova D, van Hout-Kuijer MA, Jansen JH, Huynen MA, Adema GJ. MicroRNA genes preferentially expressed in dendritic cells contain sites for conserved transcription factor binding motifs in their promoters. BMC genomics, 2011. 12(1): 330.

31. Verstappen J, Katsaros C, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW. The recruitment of bone marrow-derived cells to skin wounds is independent of wound size. Wound repair and regenerationSociety, 2011. 19(2): 260-7.

32. Eich C, de Vries IJ, Linssen PC, de Boer A, Boezeman JB, Figdor CG, Cambi A. The lymphoid chemokine CCL21 triggers LFA-1 adhesive properties on human dendritic cells. Immunology and cell biology, 2011. 89(3): 458-65.

33. de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Molecular immunology, 2011. 48(6-7): 810-7.

34. Chai LY, de Boer MG, van der Velden WJ, Plantinga TS, van Spriel AB, Jacobs C, Halkes CJ, Vonk AG, Blijlevens NM, van Dissel JT, Donnelly PJ, Kullberg BJ, Maertens J, Netea MG. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. The Journal of infectious diseases, 2011. 203(5): 736-43.

35. van Maren WW, Nierkens S, Toonen LW, Bolscher JM, Sutmuller RP, Adema GJ. Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation. BMC immunology, 2011. 12(1): 23.

36. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pfluger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of clinical oncology, 2011. 29(15): 1987-96.

37. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E, Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A, Tichelli A, Apperley J. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. Journal of clinical oncology, 2011. 29(15): 1980-6.

38. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA, Mus RD, Boerman OC, Punt CJ, Figdor CG, Oyen WJ, de Vries IJ. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A, 2011. 108(45): 18396-9.

39. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials, 2011. 32(28): 6791-803.

40. van Bijnen ST, Vermeer H, Mourisse JM, de Witte T, van Swieten HA, Muus P. Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab. European journal of haematology, 2011. 87(4): 376-8.

41. Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG, Torensma R. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. Int J Gynecol Cancer, 2011. 21(7): 1241-7.

42. Sanecka A, Ansems M, Prosser AC, Danielski K, Warner K, den Brok MH, Jansen BJ, Eleveld-Trancikova D, Adema GJ. DC-STAMP knock-down deregulates cytokine production and T-cell stimulatory capacity of LPS-matured dendritic cells. BMC immunology, 2011. 12(1): 57.

43. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood, 2011. 118(15): 4111-9.

44. Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Adema GJ, Janssen EM. Immune Adjuvant Efficacy of CpG Oligonucleotide in Cancer Treatment Is Founded Specifically upon TLR9 Function in Plasmacytoid Dendritic Cells. Cancer research, 2011. 71(20): 6428-37.

45. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res, 2011. 17(17): 5725-35.

46. Bonetto F, Srinivas M, Heerschap A, Mailliard R, Ahrens ET, Figdor CG, de Vries IJ. A Novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int J Cancer, 2011. 129(2): 365-73.

47. Desar IM, Jacobs JF, Stillebroer AB, Hulsbergen-Vandekaa CA, Oyen WJ, Mulders PF, van der Graaf WT, Adema GJ, van Herpen CM, de Vries IJ. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer, 2011. 129(2): 507-12.

48. Te Riet J, Katan AJ, Rankl C, Stahl SW, van Buul AM, Phang IY, Gomez-Casado A, Schon P, Gerritsen JW, Cambi A, Rowan AE, Vancso GJ, Jonkheijm P, Huskens J, Oosterkamp TH, Gaub H, Hinterdorfer P, Figdor CG, Speller S. Interlaboratory round robin on cantilever calibration for AFM force spectroscopy. Ultramicroscopy, 2011. 111(12): 1659-69.